The diversity of p53/p21 transactivation phenotype of p53 signaling pathway and their relationship to TP53 gene mutation and clinical outcome in diffuse large B-Cell lymphoma (DLBCL)

被引：0
|
作者：
Young, K. H.
Moller, M. B.
Colleoni, G. W. B.
Sanchez-Beato, A.
Kerbauy, F. R.
Leroy, K.
Piris, M. A.
Eickhoff, J. C.
Young, A. H.
Kanehira, K.
Cook, S.
Ranheim, E. A.
Kahl, B. S.
Olivier, M.
Campo, E.
Delabie, J.
Gaseoyne, R. D.
Rosenwald, A.
Braziel, R. M.
Jaffe, E. S.
Wilson, W. H.
Staudt, L. M.
Chan, W. C.
Weasenburger, D. D.
Greiner, T. C.
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[2] Odense Univ Hosp, DK-5000 Odense, Denmark
[3] Univ Fed Sao Paulo, Sao Paulo, Brazil
[4] Spanish Natl Canc Ctr, Madrid, Spain
[5] Hop Henri Mondor, Paris, France
[6] World Hlth Org, Lyon, France
来源：
LABORATORY INVESTIGATION | 2007年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1217
引用
收藏
页码：265A / 266A
页数：2
相关论文
共 50 条
  • [41] Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma
    Voropaeva, Elena N.
    Pospelova, Tatyana I.
    Voevoda, Mikhail I.
    Maksimov, Vladimir N.
    Orlov, Yuriy L.
    Seregina, Olga B.
    BMC MEDICAL GENOMICS, 2019, 12 (Suppl 2)
  • [42] Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma
    Elena N. Voropaeva
    Tatyana I. Pospelova
    Mikhail I. Voevoda
    Vladimir N. Maksimov
    Yuriy L. Orlov
    Olga B. Seregina
    BMC Medical Genomics, 12
  • [43] Impact of p53 positive p21 negative phenotype on outcome in CHOP-R treated DLBCL patients
    Hurst, E. C.
    Maniou-Fowler, T.
    Sieniawski, M.
    Angus, B.
    Proctor, S.
    Lennard, A.
    Culpin, R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 48 - 48
  • [44] Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma
    MB Møller
    Y Ino
    A-M Gerdes
    K Skøjdt
    DN Louis
    NT Pedersen
    Leukemia, 1999, 13 : 453 - 459
  • [45] Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma
    Moller, MB
    Ino, Y
    Gerdes, AM
    Skjodt, K
    Louis, DN
    Pedersen, NT
    LEUKEMIA, 1999, 13 (03) : 453 - 459
  • [46] ABSENCE OF MUTATION IN P21 IN BREAST CANCERS WITH WILDTYPE P53
    EVANS, AA
    PRIMROSE, JN
    ROYLE, GT
    CROOK, TR
    BRITISH JOURNAL OF SURGERY, 1995, 82 (11) : 1572 - 1573
  • [47] The impact of P53 and P21waf1 expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma
    Visco, Carlo
    Canal, Fabio
    Parolini, Claudia
    Andreoli, Annalisa
    Ambrosetti, Achille
    Krampera, Mauro
    Lestani, Maurizio
    Pizzolo, Giovanni
    Chilosi, Marco
    HAEMATOLOGICA, 2006, 91 (05) : 687 - 690
  • [48] Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
    Kobel, Martin
    Piskorz, Anna M.
    Lee, Sandra
    Lui, Shuhong
    LePage, Cecile
    Marass, Francesco
    Rosenfeld, Nitzan
    Masson, Anne-Marie Mes
    Brenton, James D.
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2016, 2 (04): : 247 - 258
  • [49] Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status
    Naso, Julia R.
    Tessier-Cloutier, Basile
    Senz, Janine
    Huntsman, David G.
    Churg, Andrew
    MODERN PATHOLOGY, 2021, : 77 - 81
  • [50] TP53 dysfunction in diffuse large B-cell lymphoma
    Lu, Ting-Xun
    Young, Ken H.
    Xu, Wei
    Li, Jian-Yong
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 97 : 47 - 55
12345